Citigroup’s Denali Therapeutics DNLI Stock Holding History

Citigroup’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-30,000	Closed	-$576K	–	5848
2026 Q1	$576K	Buy	+30,000	New	+$597K	﹤0.01%	3462

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citigroup's DNLI Position: Q2 2026 in Review

Citigroup increased its Denali Therapeutics (DNLI) stake by 1,141% in Q2 2026, buying an estimated $9.21M and bringing the position to 487,278 shares worth $12.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1451.

Citigroup first reported a position in DNLI in Q1 2018 and has held it in 34 quarters since. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Citigroup held 487,278 shares of Denali Therapeutics worth $12.5M as of Q2 2026.
Citigroup bought 448,000 Denali Therapeutics shares in Q2 2026, an estimated $9.21M.
Denali Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #1451 holding.
Citigroup first reported a position in Denali Therapeutics in Q1 2018 and has held it in 34 quarters since.
294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.